A study of the investigational drug PF-07220060 together with Letrozole compared to Letrozole alone in postmenopausal women
Zusammenfassung der Studie
The aim of this study is to investigate the effect of the investigational drug PF-07220060 plus Letrozole compared to the sole intake of Letrozole without PF-07220060 for the treatment of breast cancer. Participants will be randomly assigned (like flipping a coin) either to the treatment (PF-07220060 plus Letrozole) or to Letrozole alone. Both PF-07220060 and Letrozole will be taken orally. PF-07220060 will be taken twice daily for 14 days. Letrozole will be taken once daily for 14 days. Participants will have a pre-screening period of up to 28 days. If found eligible, they will receive a study treatment for 14 days and will then be invited for a follow-up approximately 28 days after the last dose. For all study participants, at least one biopsy will be performed during the study. A biopsy is the removal of cells or tissue for examination. A biopsy will be performed on all study participants on day 14. During the study, additional safety assessments, including blood draws and surveys by onsite staff, will be conducted.
(BASEC)
Untersuchte Intervention
In the trial: Arm A/Experimental/PF-07220060 plus Letrozole
PF-07220060 will be taken orally in tablet form twice daily for 14 days. Letrozole will be taken orally in tablet form once daily for 14 days.
Active comparator: Arm B/Control/Letrozole
Letrozole will be taken orally once daily for 14 days.
(BASEC)
Untersuchte Krankheit(en)
Breast cancer
(BASEC)
Postmenopausal women with histologically confirmed HR-positive and HER2-negative breast cancer (after local assessment) Documented estrogen receptor (ER) and/or progesterone receptor (PR) positive disease by IHC or ISH Participants must have a KI-67 score of >/= 10 % with unilateral, invasive T1c-T4c, N0-N2, and M0 breast cancer Participants must be willing and able to undergo a biopsy at baseline and on day 14 of the study, and they must have an ECOG score of 0 or 1. Participants must be eligible for breast cancer treatment and must not have received systemic therapy (e.g., chemotherapy, hormone therapy), radiation, surgery, or an investigational drug within 2 weeks prior to the collection of the diagnostic tissue sample, nor have used hormone replacement therapy (HRT) or another estrogen-containing medication (including vaginal estrogen). (BASEC)
Ausschlusskriterien
A prior systemic therapy, radiation, surgery, investigational therapy for breast cancer Certain conditions in the past 6 months, e.g.: myocardial infarction, severe unstable angina pectoris, coronary/peripheral bypass surgery, symptomatic heart failure (New York Heart Association Class III or IV), cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, or other clinically significant episode of thromboembolism Laboratory abnormalities outside the parameters specified in the protocol (BASEC)
Studienstandort
Aarau, Basel, Bern, Lausanne, Andere
(BASEC)
Baden
(BASEC)
Sponsor
Pfizer Inc 66 Hudson Boulevard East New York NY 10001 USA Sponsor’s representative in Switzerland: Martina Knecht Maier Pfizer AG Zürich
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Martina Knecht Maier
+41 78 615 62 56
martina.knechtmaier@clutterpfizer.comPfizer AG Schärenmoosstrasse 99 8052 Zürich Schweiz
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Waadt
(BASEC)
Datum der Bewilligung durch die Ethikkommission
16.12.2024
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
C4391025/AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar